Neovate Capital Partners is a brand-new investment firm record, and its full research profile isn't ready yet.
Library
neovate.vcCrawled Oct 27, 2026
Product
1 page- Portfolio | Early-Stage Advantage/portfolio
Neovate’s team has invested over $150 million through prior early-stage funds and individual investments, supporting tech and life sciences startups in reaching milestones.
Blog
6 pages- Building a Winning Board – Hits and Misses/news/building-a-winning-board-hits-and-misses
- Buying to Build - Empowering Growth with Strategic Acquisitions/news/building-to-buy-empowering-growth-with-strategic-acquisitions
- Investing in Orthopedic Startups/news/investing-in-orthopedic-startups-neovate-capital-partners
- Mapping the Medtech M&A Landscape/news/mapping-the-medtech-mampa-landscape-strategies-for-companies-in-a-changing-market
Press
6 pages- Kevin Rocco featured on State of MedTech Podcast for “$250 MedTech Exit with Kevin Rocco, Founder of Biorez”/news/kevin-rocco-featured-on-state-of-medtech-podcast-for-250-medtech-exit-with-kevin-rocco-founder-of-biorez
- Kevin Rocco Judge at Yale Innovation Summit/news/kevin-rocco-judge-at-yale-innovation-summit
- Nick Pachuda and Kevin Rocco moderator and panelists respectively for “Why the Heck Can’t I Raise Capital” at LSI USA ’24/news/nick-pachuda-and-kevin-rocco-moderator-and-panelists-respectively-for-why-the-heck-cant-i-raise-capital-at-lsi-usa-24
- Nick Pachuda as moderator for “Light at the End of the Tunnel in Medtech Financing” at LSI Europe ’24/news/nick-pachuda-as-moderator-for-light-at-the-end-of-the-tunnel-in-medtech-financing-at-lsi-europe-24-1
Contact
1 page- Contact | Get in Touch Today/contact
Neovate provides contact information for inquiries and collaborations, with offices in Denver, New Haven, Pittsburgh, and London.
Homepage
2 pages- Homepage/
Neovate invests in transformational devices and therapeutics at critical pre-inflection points, often before key commercial or clinical milestones.
- Homepage/home
Neovate invests in transformational devices and therapeutics at critical pre-inflection points, often before key commercial or clinical milestones.
